TY - JOUR
T1 - A non-toxic analogue of a coeliac-activating gliadin peptide
T2 - A basis for immunomodulation?
AU - Biagi, F.
AU - Ellis, H. J.
AU - Parnell, N. D J
AU - Shidrawi, R. G.
AU - Thomas, P. D.
AU - O'Reilly, N.
AU - Corazza, G. R.
AU - Ciclitira, P. J.
PY - 1999
Y1 - 1999
N2 - Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H). Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic. Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.
AB - Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H). Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic. Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.
UR - http://www.scopus.com/inward/record.url?scp=0033001147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033001147&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.1999.00512.x
DO - 10.1046/j.1365-2036.1999.00512.x
M3 - Article
C2 - 10383530
AN - SCOPUS:0033001147
SN - 0269-2813
VL - 13
SP - 945
EP - 950
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 7
ER -